Astrazeneca (AZN) Stock
Global pharmaceutical giant developing prescription medicines for patients. Here's the price, business snapshot, and what's worth knowing about Astrazeneca in October 2026.
AstraZeneca PLC (AZN) is a large‑cap global biopharmaceutical company focused on discovery, development and commercialisation of prescription medicines, with particular strength in oncology, cardiovascular, renal & metabolic (CVRM), and respiratory therapies. The firm combines a broad marketed portfolio with an active R&D pipeline and significant investment in biologics and precision medicines. For investors, key considerations include steady revenue from established drugs, growth driven by newer oncology and rare‑disease launches, and continued R&D spend that can both support long‑term value and create near‑term earnings variability. The company operates globally, exposing it to different regulatory and pricing environments and currency movements. AstraZeneca has historically paid dividends, but dividend levels and share price can fluctuate with trial outcomes, patent expiries and competition. This summary is educational only — not personalised investment advice — and investors should weigh growth potential against clinical, regulatory and commercial risks.
Why It’s Moving
AstraZeneca Rallies on $2B Summit Deal, New R&D Hub, and Upgraded Analyst Targets
- Strategic Oncology Expansion: AstraZeneca completed a $2 billion equity investment in Summit Therapeutics and entered a clinical collaboration with Daiichi Sankyo to test ivonescimab combined with Datroway across lung and breast cancers, positioning the company at the forefront of next-generation cancer care combinations.
- US Infrastructure Growth: The company announced a new global strategic R&D center in Kendall Square, Cambridge, Massachusetts, committing over $1 billion as part of a broader $50 billion US investment plan expected to expand its local workforce by more than 50%.
- Analyst Confidence Boost: Citi raised its price target to £186 citing improved prospects for tozorakimab, while Jefferies maintained a 'buy' rating ahead of Q3 earnings, forecasting revenue and core earnings to beat consensus estimates.
AstraZeneca Rallies on $2B Summit Deal, New R&D Hub, and Upgraded Analyst Targets
- Strategic Oncology Expansion: AstraZeneca completed a $2 billion equity investment in Summit Therapeutics and entered a clinical collaboration with Daiichi Sankyo to test ivonescimab combined with Datroway across lung and breast cancers, positioning the company at the forefront of next-generation cancer care combinations.
- US Infrastructure Growth: The company announced a new global strategic R&D center in Kendall Square, Cambridge, Massachusetts, committing over $1 billion as part of a broader $50 billion US investment plan expected to expand its local workforce by more than 50%.
- Analyst Confidence Boost: Citi raised its price target to £186 citing improved prospects for tozorakimab, while Jefferies maintained a 'buy' rating ahead of Q3 earnings, forecasting revenue and core earnings to beat consensus estimates.
Sixth Month Growth Performance
When is the next earnings date for ASTRAZENECA PLC (AZN)?
Astrazeneca has not yet announced a confirmed date for its next earnings release. Based on the company's historical reporting pattern of releasing results approximately three months after the previous quarter, the next report is expected in late October 2026. This upcoming disclosure will cover financial performance for the third quarter of 2026. Investors should monitor official channels for the precise scheduling of this Q3 earnings call.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying AstraZeneca's stock, indicating a strong potential for price increase.
Financial Health
AstraZeneca is performing well with strong revenue, profits, and cash flow, indicating solid financial health.
Dividend
AstraZeneca's average dividend yield of 3.31% offers a reasonable return for those seeking dividend income. If you invested $1000 you would be paid $33.10 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Pipeline drives growth
AstraZeneca’s R&D pipeline, especially in oncology and precision medicines, can support future revenue, though trial outcomes and approvals are uncertain.
Global footprint matters
Wide geographic reach diversifies revenue but brings exposure to regulatory, pricing and currency risks that can affect results.
Innovation and spending
Heavy investment in biologics and new modalities underpins long‑term potential while creating earnings variability in the near term.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
